According to filings with the U.S. Securities and Exchange Commission, GT Medical Technologies is raising $45,137,701.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Matthew Likens played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About GT Medical Technologies
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The companys first product, GammaTile is protected by 10 US and 2 Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement.

To learn more about GT Medical Technologies, visit http://www.gtmedtech.com/

Contact:
Matthew Likens, Chief Executive Officer
480-619-4069
https://www.linkedin.com/in/matthew-likens-3a97834/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.